Introduction
Acquired immune deficiency syndrome (AIDS), caused by HIV-1, was first reported in the USA in 1981 (Barré-Sinoussi et al., 1983) . This disease has infected 60 million people (Baleux et al., 2009 ) and has been a worldwide public health problem for the past 30 years. Tremendous efforts have been made to treat and prevent HIV-1 infection. Now .30 antiretroviral drugs are available for clinical use, which have alleviated patient suffering and improved the quality of life for people infected with HIV.
Most of the antiretroviral drugs target two HIV-1 enzymes, the protease and reverse transcriptase, designated as protease inhibitors (PIs) and reverse transcriptase inhibitors (RTIs), respectively. Nonetheless, the emergence of drug resistance and toxic side effects in PIs and RTIs treatment has motivated the development of new therapeutics with novel mechanisms of action (Shafer and Schapiro, 2008) . One of the most promising recent strategies is the blocking of viral entry.
The entry of HIV-1 into the host cell requires fusion of the viral membrane with the cellular membrane. This fusion is mediated by the HIV-1 envelope glycoprotein (Env). HIV-1 Env is composed of a transmembrane (TM) glycoprotein (gp41) and a surface glycoprotein (gp120) (Kilby et al., 1998; Liu et al., 2008) . HIV gp120 binds to the CD4 receptor, as well as to chemokine co-receptors (CXCR4 or CCR5), on target cells. A series of conformational changes in gp41 triggers the fusion of the viral and cellular membranes, promoting the entry of HIV-1 into the cell and subsequent proliferation (Chan et al., 1997) . HIV gp41 consists of cytoplasm (CT), TM, and extracellular domains (ectodomain). The ectodomain includes a fusion peptide, an N-terminal heptad repeat (NHR), a C-terminal heptad repeat (CHR) and a tryptophan-rich (TR) region. In the fusion process, gp41 undergoes a large-scale conformational transformation from native into prehairpin intermediate and ultimately into post-fusion trimer-of-hairpins structure. Finally, the formation of the fusion pore mediates the joining of the viral and cellular membranes (Kahle et al., 2009; Pan et al., 2010; Weiss, 2003) . The post-fusion trimer-of-hairpins is a six-stranded a-helix bundle (6-HB) structure consisting of an N-terminal trimeric gp41 a-helical coiled coil and the antiparallel packing of three gp41 C-terminal a-helices into the grooves of the core (Weissenhorn et al., 1997; Harrison, 2005; Luftig et al., 2006) . Preventing the formation of the 6-HB structure may limit HIV infection. The peptides derived from the NHR and CHR, designated N-and C-peptides, respectively, competitively bind to endogenous viral gp41 CHR and NHR to block the formation of the 6-HB. The first N-peptide fusion inhibitor was T21, and the first C-peptide inhibitor was SJ-2176. T20, C34 and others came later (Wild et al., 1992; Jiang et al., 1993; Wild et al., 1993; Lu et al., 1995) , in which T20 was approved by US FDA as the first HIV fusion inhibitor to treat HIV/AIDS in 2003.
The clinical use of peptidic fusion inhibitors has been limited by the high cost of synthesis and their short half-life in vivo. To overcome these shortcomings, we have designed previously a recombinant peptide C52L that can be expressed in bacteria. We showed that this peptide can potently inhibit the infection of human T cells by diverse HIV-1 viruses in vitro (Deng et al., 2007) . However, this peptide is expressed in inclusion bodies. In the present study, we applied the method of Kunkel (Kunkel et al., 1987) to modify C52L and obtained a new peptide L15 with greater a-helical content and equivalent antiviral activity. L15 is soluble when expressed in bacteria, making production more convenient and economical.
Materials and methods

Mutation, expression and purification
Plasmid pC52L, encoding C52L, was generated by the laboratory previously (Deng et al., 2007) . All of the mutants were created using pC52L as a template and the method of Kunkel (Kunkel et al., 1987) . Residues at positions a, d, e and g of C52L were replaced by leucine. Residues at positions b, c and f were substituted with glutamine. All the mutations were confirmed by DNA sequencing. C52L and all the mutated peptides were expressed in Escherichia coli BL21-(DE3) strain (Novagen). The bacteria were cultured at 378C in 800 ml of Luria-Bertani (LB) medium supplemented with kanamycin (30 mg/ml) until the optical density at 600 nm (OD600) was 0.5. The recombinant proteins were induced by incubating the cells with Isopropyl b-D-1-thiogalactopyranoside (final concentration, 0.6 mM) for 5 h at 378C. Cultured bacteria were then harvested by centrifugation (Beckman) at 5000 rpm for 15 min at 48C. The pellets were resuspended in buffer A (50 mM Tris-HCl, pH 8.5) and centrifuged again. The bacterial pellets were then fast-frozen in liquid nitrogen and stored at 2808C. During purification, the bacterial pellets were placed at 48C to be freeze -thawed overnight. Thawed bacteria resuspended in buffer B (50 mM Tris-HCl, 1 mM EDTA, 25% sucrose, pH 8.5) were lysed by incubation with lysozyme for 1 h at 48C and sonication at 08C. The lysed cells were centrifuged (35 000 g for 15 min) to separate the soluble and insoluble fractions. If the peptides were expressed solubly, the supernatant was salted out with 20% saturated ammonium sulfate and centrifuged (1000 g, 48C, 10 min). The precipitate was dialyzed with buffer A and filtered with a 0.2 mM membrane. The sample was then loaded onto a diethylaminoethyl (DEAE) Sepharose column (GE Healthcare, Easton Turnpike, Connecticut, USA) preequilibrated in buffer A, and eluted using a gradient of NaCl (0-1 M) in buffer A. For insoluble peptides, the inclusion bodies were washed and then loaded onto the DEAE column as described previously (Deng et al., 2007) . The expressed samples were confirmed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) on a 16.5% tricine gel with Coomassie blue staining. All the purified peptides were dialyzed in buffer A overnight and then freeze -dried. N46 was synthesized by GL Biochem (Shanghai, China). The plasmid p5-Helix, constructed with the pAED4 vector (Root et al., 2001) , was amplified in E.coli MM294 strain grown in LB medium containing ampicillin (30 mg/ml). The 5-Helix was prepared in E.coli BL21-(DE3)/pLysS strain grown in LB medium containing ampicillin (30 mg/ml). Inclusion bodies were washed, loaded onto a DEAE column and purified with the steps described above.
The peptide concentration was determined by measuring UV absorbance at 280 nm of the peptide in 6 M guanidine hydrochloride. The molar extinction coefficient (1) was calculated based on the number of tryptophan (Trp) residues and tyrosine (Tyr) residues. The 1 of one Trp and Tyr is 5500 and 1490 mol l 21 cm
21
, respectively.
Circular dichroism spectroscopy
All the peptides were tested at 10 mM in phosphate-buffered saline (PBS; pH 7.2). The circular dichroism (CD) spectra of these samples were obtained on the Chirascan (Applied Photophysics Limited, Leatherhead, Surrey, UK) at 48C using a 1.0 nm bandwidth, 1 mm cell, 1.0 nm step, 0.5 s time-per-point and 1.0 min time internal. The value for the buffer alone was measured and subtracted from the peptide spectra. The CD spectra of all of the peptides were acquired as 'ellipicity' in millidegrees u. The data were converted to the mean residue ellipticities ([u] , in degree cm 2 dmol 21 ), as described previously (Greenfield, 2006) . [u] at 222 nm of 233 000 deg cm 2 dmol 21 was regarded as 100% helix. The helical content of the peptides was estimated using the [u] value at 222 nm to divide 233 000 deg cm 2 dmol 21 (Chen et al., 1974) .
Native polyacrylamide gel electrophoresis
N-peptide and C-peptide have a tendency to form 6-HB when they are mixed in an equal molar ratio at a final concentration of 100 mM and incubated at 378C for 30-60 min. Native polyacrylamide gel electrophoresis (N-PAGE) can be used to detect the formation of the 6-HB by the N-peptide and C-peptide. The 5-Helix and the C-peptide (L14, L15 or C52L) were incubated for 30 min (final concentration of each peptide was 100 mM). Then the mixture was loaded onto a 16.5% tricine gel (10 Â 1.0 cm). The gel was stained with Coomassie blue and then photographed.
Enzyme-linked immunosorbent assay
We used enzyme-linked immunosorbent assay (ELISA) to measure the binding between N46 and the selected L14 and L15 mutant C-peptides. The plate was coated with 100 ml rabbit polyclonal immunoglobulin G (IgG) against 6-HB (no. 363) at 1 mg/ml in 0.1 M Tris-HCl ( pH 8.8) overnight at 48C. The coated plate was washed three times and blocked with 2% non-fat milk for 1 h at 378C. Then the wells were washed three times. Meanwhile, 40 ml of N46 at 2 mM (in PBS) was mixed with 40 ml C52L and selected mutants at 2 mM and incubated for 30 min at 378C. For the titration assay, 40 ml of 2-fold diluted N46 from 2 mM was incubated with 40 ml C52L and selected mutants at 2 mM. Aliquots of 60 ml of the above mixture were transferred to the corresponding wells and incubated at 378C for 1 h. The plate was washed three times, and then 100 ml monoclonal antibody (mAb) NC-1 at 1 mg/ml in PBS was added to the plates. The plate was incubated at 378C for 1 h and then washed three times. The biotin-labeled goat anti-mouse IgG (i.e., 100 ml; 1:10 000) in PBS was added, and the samples were incubated at 378C for 1 h. The plate was again washed three times, and then streptavidin-labeled horseradish peroxidase (SA-HRP, 1: 20 000) in PBS was added. The plate was incubated at 378C for 1 h and washed six times. 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) was added and allowed to react for several minutes. The reaction was stopped with 100 ml of 1 N H 2 SO 4 . The optical density at 450 nm was measured with an ELISA reader (Tecan Genious, Durham, NC). All washing steps were performed with PBS at pH 7.2 plus 0.1% Tween-20 (PBS-T).
HIV inhibition assay
The ability of the peptides to inhibit infection by laboratory-adapted HIV-1 IIIB was determined as described previously (Liu et al., 2005) . Briefly, 1 Â 10 4 MT-2 cells were infected with HIV-1 IIIB at a dosage of 100-fold 50% tissue culture infective doses (TCID 50 ) in the presence or absence of peptides at varying concentrations at 37 8C overnight. Culture supernatants were then replaced with fresh medium. On the fourth day post-infection, culture supernatant was collected and mixed with equal volumes of 5% Triton X-100. Those viral lysates were assayed for p24 antigen using ELISA as previously (Liu et al., 2005) . In brief, wells of 96-well polystyrene plates were coated with 5 mg/ml anti-p24 mAb (183-12H-5C) in 0.85 M bicarbonate buffer ( pH 9.6) at 4 8C overnight. Wells were washed with PBS-T and blocked with 2% dry fat-free milk in PBS. Viral lysates were added to the wells and incubated at 378C for 1 h. After washing three times, HIVIG, biotin-labeled goat anti-human IgG, SA-HRP and TMB were added sequentially. To terminate the reactions, 1 N H 2 SO 4 was added. The absorbance at 450 nm was measured with an ELISA reader (Tecan).
To measure the ability of the peptides to block infection by laboratory-adapted HIV-1 BaL , the viruses at 100 TCID 50 were incubated with peptides at varying concentrations at 378C for 30 min prior to the addition of the mixtures to 1 Â 10 4 TZM-b1 cells (obtained from NIH AIDS Research and Reference Reagent Program, Germantown, Maryland, USA). After 48 h of co-culture, the cells were washed once with PBS and then lysed with the lysis buffer supplied by the luciferase kit (Promega, Madison, WI, USA). Aliquots of cell lysates were transferred to 96-well, flat-bottomed luminometer plates (Costar), followed by addition of the luciferase substrate (Promega). The luciferase activity was measured with an Ultra 384 luminometer (Tecan).
Proteinase K digestion assay
Peptide (30 ml at 50 mM) was mixed with the proteinase K (working concentration of 0.5 mg/ml), and then the mixture was incubated at 378C. At different time points (0, 2, 5 and 15 min), 10 ml samples were removed and mixed with 1 ml of PMSF (Genview company, Galveston, Texas, USA) in ethanol at 10 mM to stop the reaction. The samples were added to the loading buffer and then subjected to SDS-PAGE on a 16.5% tricine gel. Coomassie blue staining was used to visualize the degradation of the peptide. Then the gels were scanned on a gel imaging system (UVP Company, Upland, California, USA) to make quantitative analysis of the peptides digested by protease K.
Results
Asn656Leu and Glu659Leu substitution of C52L alone induces soluble expression
By competitively interacting with the viral NHR, C-peptides can retard the formation of 6-HB, and thus prevent the fusion of the viral and cellular membranes. This conformational transition can be accompanied by the loss of a large amount of energy needed to stabilize the coiled-coil structure (Judice et al., 1997; Jin et al., 2000; Sia and Kim, 2003) . We demonstrated previously that the engineered peptide C52L, which has a large degree of helicity, could impart favorable binding to the triple-stranded N-peptidic coiled coil to a greater extent than a C-peptide in a random coil (Deng et al., 2007) . Coiled-coil proteins have a characteristic of seven-residue repeat, designated as (a, b, c, d, e, f and g)n. Hydrophobic residues occupy positions a and d (Harbury et al., 1993) . These hydrophobic amino acids are critical for stabilizing the coiledcoil conformation (Greenfield, 2006) . The crystal structure of the gp41 core revealed that the residues at positions a and d of the C-peptide helix are packed against the e and g side chains on the surface of the N-peptidic coiled-coil trimer. We applied leucine scan mutagenesis to C52L, hoping to obtain mutants with improved helicity that would stabilize the coiled-coil structure and strengthen the hydrophobic interaction. The residues at the positions a, d, e and g were replaced by leucine (Fig. 1A) . In addition, because C52L accumulates in inclusion bodies, it is necessary to improve the solubility of C52L in bacterial cells. Polar residues occupy positions b, c and f of the heptad, and so we applied glutamine scanning mutagenesis to substitute the amino acids at these positions with glutamine (Fig. 1B) . All the mutated plasmids were confirmed by DNA sequencing. In total, we generated 21 mutants with leucine substitution and 20 mutants with glutamine substitution. 
Soluble expression of C52L by leucine substitution
All of the 41 mutant plasmids were transformed into E.coli BL21 (DE3) strain. Peptides bearing the substitutions of Asn656 ( position a) and Glu659 ( position d) with leucine (designated L14 and L15, respectively) were found in the supernatants of lysed cells, as determined by gel electrophoresis (Fig. 2) . All the other mutated peptides were still found in inclusion bodies. These data indicate that the residues at positions 656 and 659 may play an important role in supporting a conformation that allows for soluble expression. To purify the peptides, we first salted out the soluble supernatants with 20% saturated ammonium sulfate. Precipitants were dialyzed in buffer A and then loaded onto a DEAE Sepharose column (GE Healthcare) at 48C for further purification.
Substitution of Asn656 and Glu659 of C52L with alanine alone results in insoluble expression
The above results indicate that the glutamine substitutions do not affect solubility. Only two leucine substitutions at a single site (Asn656 and Glu659) were found to support soluble expression. We then mutated Asn656 and Glu659 to alanine (designated A14 and A15, respectively) using the same method. Both mutants were confirmed by DNA sequencing and expressed and purified using the methods mentioned above. However, A14 and A15 were still mainly found in the insoluble bacterial inclusion bodies (Fig. 3) . Based on these data, we conclude that the hydrophobic single leucine substitution at 656 and 659 position results in a conformational change that may in turn contribute to the transition from insoluble to soluble.
Asn656Leu and Glu659Leu substitution alone can increase the helical content of C52L significantly
The far UV (200 -260 nm) CD spectra of C52L and all of the mutants were detected by circular dichroism spectroscopy. The [u] at 222 nm for all the peptides except for L14, L15, A14 and A15 are consistent with that of C52L. The helical contents of L14, L15, A14, A15 and C52L were found to be 88, 94, 48, 66 and 45%, respectively (Fig. 4) . Therefore, the helical content of A14, A15, L14 and L15 was higher than that of the wild-type C52L, and the L14 and L15 has the much higher helix content, indicating that the leucine replacements at the positions of Asn656 and Glu659 are likely to stabilize the helical conformation of C52L, which may contribute to solubility in E.coli expression.
Substitutions at Asn656 and Glu659 do not change the ability of C52L to form 6-HB with triple-or single-stranded N-peptides
The 5-Helix protein, containing five of the six a-helical coils, lacks a third C-peptide helix. This vacancy is a highaffinity binding site for the CHR domain of gp41 or a C-peptide (Root et al., 2001) . The binding ability of 5-Helix to the CHR domain of gp41 makes this protein a potent inhibitor to block HIV-1 membrane fusion. We performed N-PAGE to investigate whether the mutated peptides, including L14, L15 and C52L, could bind to the triple-stranded N-peptide coiled coil. We incubated these peptides with 5-Helix at 378C for 30 min. The final concentration of each peptide was 100 mM. We found that all the peptides could bind to 5-Helix to form a complex (Fig. 5A ). This result suggests that all of these peptides can interact with the NHR of gp41 to form the 6-HB.
An ELISA was used to measure a possible interaction of these selected peptides with the single-stranded N-peptide N46. The N-peptide and C-peptide tend to form a stable 6-HB that is recognized by NC-1, which is a conformationspecific mAb (Jiang et al., 1998; Jiang et al., 1999) . Our results suggest that all the selected mutated peptides and the wild-type peptide can interact with N46 ( Fig. 5B) and have a same tendency to form the 6-HB (Fig. 5C ).
The Glu659Leu form of the C52L peptide has an equivalent anti-HIV potency as the parental peptide
We compared the ability of C52L and the selected mutants to inhibit infection by laboratory-adapted HIV-1 IIIB (subtype B, X4). The IC 50 value of L15 mutant is about 57 nM, which is equivalent to that of wild type C52L with an IC 50 value of 55 nM (Table 1) . Similar results were obtained when we tested the C-peptides against HIV-1 BaL (subtype B, R5). The IC 50 of L15 against infection by HIV-1 BaL was found to be 78 nM, which is comparable to the 72 nM IC 50 value obtained for C52L (Table 1) . L14, however, showed no inhibitory effects on infection by either laboratory-adapted virus. Therefore, L15 is a possible HIV-1 fusion inhibitor with good secondary structure stability and expression solubility.
Glu659Leu substitution of C52L is more resistant to protease digestion
Poor metabolic stability has hampered the use of C-peptides as clinical antiretroviral drugs. One strategy to improve the sera half-life (t 1/2 ) of these peptides is to increase the percentage of secondary structures, such as a-helices and b-sheets (Adessi and Soto, 2002) . We found that L15 is soluble in bacteria expression and possesses activities against the infection by different HIV-1 strains that are comparable to those of C52L. Importantly, L15 also displays well-folded secondary conformations. Thus, we tested the sensitivity of L15 and C52L to proteinase K digestion. In this experiment we found that in the second minute, 50% of the C52L was digested but only 37% of L15 was digested. In the fifth minute, 90% of the C52L was digested, while 60% of the L15 still remained (Fig. 6) . Therefore, L15 remained rather stable within a 15-min digestion, whereas C52L was degraded within this same period of time. This result is consistent with our speculation that L15 has a higher amount of secondary structure and is thereby more resistant to proteinase K digestion.
Discussion
In the present study, we used leucine and glutamine scanning mutagenesis to systematically investigate the residues that affect the structural stability and solubility during the bacterial expression of C52L. Leucine was used as a single substitution because leucine is a strong helix-promoting residue and can contribute to stabilizing hydrophobic interactions (Lyu et al., 1990; O'Neil and DeGrado, 1990; Chakrabartty et al., 1994) . Interestingly, we found that the substitutions of Fig. 4 Analysis of the secondary structures of peptides. Analysis of the secondary structures of peptides of C52L, A14, A15, L14 and L15. The circular dichroism spectra were acquired at 48C on chirascan. These peptides were detected in PBS at a final concentration of 10 mM. Asn656 or Glu659 with leucine could not only make the protein soluble during E.coli expression but also enhance the helical content. It is inferred that the residue replacement at either of these key positions greatly affects the secondary structure, which contributes to the change in expression solubility. The substitution at position 656 or 659 with alanine, however, can also enhance the helical content of C52L, although the helical content is lower than that in the variants containing leucine replacements. The expression solubility was not obviously affected by alanine replacement, however. These data showed that the hydrophobic side chain of leucine in L14 and L15 could enhance a-helical secondary structure, which might contribute to the improved solubility. Therefore, the hydrophobic side-chain of leucine at position 656 (a) or 659 (d) plays a key role in determining a-helical propensity.
The C-peptides can form 6-HB with gp41 NHR or N-peptides. Although the helical contents of the C52L mutants are different, we did not find the difference of the ability to form 6-HB with N-peptides, either triple-stranded N-peptides, such as 5-Helix, or single-stranded N-peptides, such as N46. Even C34, a random structure C-peptide, can form 6-HB with N-peptides efficiently. Therefore, the substitutions of the Asn656 or Glu659 of C52L have no obvious influence on the 6-HB formation with N-peptides, though we cannot rule out the possibility the stability of 6-HB may have some difference.
C52L is a potent HIV fusion inhibitor. We then tested whether the mutation peptides can inhibit HIV infection.
L15 displayed comparable anti-HIV potency, while L14 failed to display anti-viral activity as the wild-type C52L. Although L14 can also form 6-HB with N-peptides such as L15, the inhibitory activity against HIV infection may still be different. We have shown previously that mutated C34 peptides at Asp632 have different anti-HIV potency, though all of them can still form 6-HB with N36, an N-peptide derived from gp41 NHR (He et al., 2008) . Furthermore, T-20, the C-peptide which cannot form 6-HB with N36 or N46, can inhibit HIV entry and infection potently (Liu et al., 2005) . Therefore, L15 is a potent HIV fusion inhibitor with the advantage of soluble expression in E.coli, which makes this mutant peptide a more attractive anti-HIV therapeutic since it can be made more convenient and economical.
The development of peptides as therapeutic drugs could be difficult, in part because of their sensitivity to proteases (Yang et al., 1999) . To explore the possibility of L15 as a new peptidic antiretroviral drug, we observed the sensitivity of the L15 and C52L to proteinase K digestion in parallel experiments. As we know, protease has a preference to hydrolyze unfolded substrates (Lu et al., 1995; Lu and Kim, 1997; Lu et al., 1999) . Because of proteinase K possessing low specificity, it may act on each one of these peptide bonds in a protein exposed to proteolysis (Yang et al., 1997) . Information about the primary structure of the protein can be determined by proteinase K digestion (Lu et al., 1995; Yang et al., 1997) . Proteinase K digestion was often chosen to indirectly investigate stability of mutant peptides in vivo. Because L15 has a greater degree of secondary structure, it was expected to have a higher resistance to proteolytic digestion than the wild-type peptide. From our experiments, we found that L15 is much more stable against proteinase K digestion than C52L within this same period of time. The increased resistance of L15 to proteinase K digestion suggests that this peptide may have a longer half life (t 1/2 ) than C52L when used as anti-HIV drug.
Besides treatment of HIV/AIDS patients, the prevention of HIV transmission is much more important. An alternative to vaccination is the application of microbicides that prevent the vaginal epithelium from being infected by HIV during sexual intercourse. There is a higher rate of HIV infection in woman compared with men, which has been attributed to both physiological susceptibility and social discrimination. In some cases, women cannot ask for condom usage to protect themselves (Doncel and Mauck, 2004; Rohan and Sassi, 2009) . Microbicides, which can be controlled by women, may reduce the rate of HIV infection. A recent clinical trial in South Africa showed that the use of tenofovir gel as a topical microbicide can reduce 39% of the HIV infection compared with the placebo gel (Abdool Karim et al., 2010) . This specific anti-retroviral drug shows convincing effectiveness in the protection of HIV sexual transmission when used as a microbicide. Lactobacilli is a major component of the vaginal microflora and has been regarded as a natural defense barrier against HIV and other sexually transmitted diseases. To enhance its prevention effect, Lactobacilli can also be genetically modified to secrete anti-HIV agents, such as C52L or T-20 (Medaglini et al., 1997; Liu et al., 2006) . Here, we present the peptidic inhibitor L15, which is soluble, has anti-HIV activity and has a stable secondary structure. This peptide may also be developed into a potent microbicide that can be secreted solubly by vaginal Lactobacilli. 
